A ministerial-level meeting took place on 25 March in South Africa, aiming to harmonize tracking, tracing, diagnosis and referrals for people affiliated with southern Africa's lucrative mining sector -- all of whom are at high risk for contracting tuberculosis.
You are here
On 7–8 November 2013, the Global Fund Board held its 30th meeting in Geneva, Switzerland. GFO was present, with observer status. The main decisions made at the meeting, in chronological order, were as follows. (For precise wording of what the Board agreed, see the decision points document that has been posted here.
On 14–15 November 2012, the Global Fund Board held its 28th meeting in Geneva, Switzerland. GFO was present, with observer status. The main decisions made at the meeting, in chronological order, were as follows. (For precise wording of what the Board agreed, see the decision points document that has been posted here.
Editor’s Note: This explanation of the broad elements of the new funding model is based on the decision point adopted by the Board. Not everything in the decision point is clear, so this explanation includes some interpretation by Aidspan. Readers are advised to check with the Global Fund Secretariat if they have questions.
The Secretariat is making a special effort to fix what it calls “stuck grants.” These are grants to which no money has flowed within the first three months after signature of the grant agreement or, for more mature grants, to which no money has flowed within the last six months. This information is contained in the report prepared for the Board meeting in Geneva by General Manager Gabriel Jaramillo.
Editor’s Note: Included in this summary is the Board decision on the broad elements of the new funding model.
The Global Fund is developing a comprehensive performanceassessment framework designed to enhance its ability to identify CCMs that needassistance. As well, fund portfolio managers (FPMs) have been instructed to activelyparticipate in CCM meetings and to liaise more regularly with CCM members.
The Global Fund's Board completed a three-day meeting in Geneva on Friday that reached solid agreement on multiple strategic issues that could easily have led to dissent.
At its October 2002 meeting, the board decided that if a medicinal product is to be eligible for purchase using Global Fund grants, it must meet various requirements.
Several board members commented on the fact that at present, only $300 million of the anticipated $1,000 million cost of Round 5 has been promised. This led to a resolution saying "The Board notes with concern the current shortfall regarding funds available for Round 5. The Board calls upon participants of the Replenishment Conference, and all other potential donors, to take urgent action to ensure that Round 5 is fully funded."